Partnership with Unither Pharmaceuticals to develop a new product to treat pain

January 2017. Unither Pharmaceuticals and Aptys Pharmaceuticals start the development of an innovative product to treat moderate to severe pain  

« We are delighted to collaborate with Aptys Pharmaceuticals, a company well-known in the field of innovative formulation development » declares Eric Goupil, President and CEO of Unither Pharmaceuticals.

« We are very pleased with this partnership with Unither Pharmaceuticals which will bring all its experience in pharmaceutical, clinical and regulatory development» adds François Boutignon, President and CEO of Aptys Pharmaceuticals.

APTYS strengthens its management

Michel FRADIN, COO and Responsible Pharmacist and Luc BRZUSTOWSKI, CFO have joined APTYS Pharmaceuticals.

Michel holds a Doctorate in Pharmacy and a PhD in Pharmaco-Chemistry. He has 26 years of  international pharmaceutical industry experience.
At MERCK SHARP & DOHME, his main positions were Head of Pharmaceutical Technical Operations Department, Responsible Pharmacist and Regional Business Operations Director (Europe Middle East Africa).
Luc is a certified Accountant and holds a Master in Business Procedural Law.
He has more than 32 years of experience in finance, including corporate finance, audit and fund raising. He worked with several Accounting firms such as KPMG and COFEXCE. In 1994, he founded his own firm.

New equipment / New offer

  • a Micro-analytical balance PE26 (METTLER) hosted in
  • a special Safety weighing enclosure ST1-900 to weight potent substances (SAFETECH)
  • a Washer-disinfector for processing analytically clean laboratory glassware  (MIELE)
  • an Amperometric detector for determining electroactive components (METHROM)

Aptys & Inhalexpert at CPHI/ICSE Madrid

Francois Boutignon and Pascal Cavaillon will be present during the CPHI /ICSE fair in Madrid.
This will be a good opportunity for you to learn more about our “Formulation & Analytical Services and Expertise” in the field of the development of complex products (NTE, generic plus).

We hope seeing you in Madrid.

Viramal Limited and Aptys Pharmaceuticals SAS: Collaboration on Phase III Clinical Development of Hormone Therapy

Viramal Limited, a UK-based biotechnology company and Aptys Pharmaceuticals SAS, a France-based contract research organisation (CRO) are pleased to announce their collaboration on hormone therapies. Viramal has acquired from Aptys a worldwide exclusive license for TestoCream, a unique testosterone hormone therapy. Aptys will continue to provide contract research services as the product completes its Phase III clinical development. Viramal CEO, Oliver Bates, commented “We are very excited to embark on this collaboration with Aptys. Aptys has made significant contributions to TestoCream over the past few years including commercial scale manufacturing of the product. TestoCream will be launched when a marketing approval has been obtained from the US FDA. Aptys CEO, Francois Boutignon, commented “I’m glad to have Viramal with its expertise as a partner to complete the development of TestoCream, and bring the product to the market.

About Viramal Limited: Viramal is a biotechnology company with a portfolio of hormone therapies, which includes TestoCream and therapies in pre-clinical and early clinical development stages. Viramal expects to file a New Drug Application with the FDA for TestoCream in 2016. About Aptys Pharmaceuticals SAS: Aptys Pharmaceuticals SAS is a CRO with expertice in design and development of formulations and analytical methods. With fully equipped laboratories located in the south of France, the company can develop custom made or generic dosage forms. Also, the company offers analytical methods development and validations as well as ICH stability studies. Finally, Aptys is pleased to offer its proprietary drug technologies, especially for transdermal and topical delivery.

For more information, contact: Viramal Limited Oliver Bates, CEO Viramal Limited 48-49 Russell Sq London WC1B 4JP Aptys Pharmaceuticals SAS Francois Boutignon, CEO Aptys Pharmaceuticals SAS Biopôle Clermont-Limagne 63360 Saint-Beauzire